- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03007446
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Gastric cancer is the second most common cause of cancer-related deaths worldwide, and surgical resection during the early stage has improved treatment outcomes.However, many patients are diagnosed with unresectable advanced or metastatic stage disease losing the radical surgery opportunity. Systemic chemotherapy is the leading treatment that prolongs survival times for such patients.
Approximate 20 patients with unresectable gastric cancer will be enrolled in this study,the investigators will evaluate the efficacy and security of Apatinib + SOX(oxaliplatin+S-1) for unresectable gastric cancer.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Beijing, China, 100853
- Rekrutierung
- The Chinese PLA General Hospital
-
Kontakt:
- Lin Chen, Master
- Telefonnummer: 13801290395
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histologically proved gastric adenocarcinoma;
- At least a unresectable factor before operation via CT, MRI, or PET-CT: difficult resection of locally advanced gastric cancer(T4b); hepatic metastasis (H1; at most five lesions, total diameter ≤8 cm); Peritoneal metastasis(CY1, P1) ;
- Definitely diagnosed as unresectable gastric cancer via exploratory laparoscopy or laparotomy;
- ECOG performance status 0-2;
- Age 18-70 years old, Life expectancy estimated than 3 months;
For results of blood routine test and biochemical tests:
- Hgb ≥ 80g/L,
- WBC ≥ 4000/mm3,
- ANC ≥ 1.5×109/L,
- platelets ≥ 80×109/L
- ALT and AST ≤ 2.5 x upper normal limit (UNL), and ≤ 5 x UNL(Hematogenous metastases),
- Serum Total bilirubin ≤ 1.5 X UNL,
- Serum Creatine ≤ 1.5 x UNL ;
- Good cardiac function before the recruitment, no seizure of myocardial infarction in past half years, and controllable hypertension and other coronary heart disease;
- Not concomitant with other uncontrollable benign disease before the recruitment(e.g. the infection in the kidney, lung and liver);
- informed consent.
Exclusion Criteria:
- Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction; Patients with positive urinary protein;
- Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
- Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;
- Contraindications include allergy to apatinib and/or its accessories, active bleeding, intestinal perforation, intestinal obstruction, within 30 days after surgery, drugs with poor-controlled hypertension, Class Ⅲ-Ⅳ cardiac dysfunction (NYHA standard), severe hepatic and renal dysfunction(level 4)if apatinib use is considered;
- Abnormal Coagulation (INR>1.5, APTT>1.5 UNL), with tendency of bleed;
- Pregnant or lactating women;
- Any other condition that might place the patient at undue risk or preclude a patient from completing the study;
- Treatment with prior radiotherapy, chemotherapy, Targeted therapy or immunotherapy;
- Other conditions regimented at investigators' discretion.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Apatinib plus Oxaliplatin/S-1
|
Apatinib :A starting dose of apatinib was administered 500 mg daily
Andere Namen:
Oxaliplatin:130 mg/m2,d1,ivgtt,in a 21 day cycle
S-1:40mg,bid,d1-14,po,in a 21 day cycle.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
reaction rate
Zeitfenster: 4 months
|
4 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Nebenwirkungen
Zeitfenster: 6 Monate
|
6 Monate
|
Gesamtüberleben
Zeitfenster: 3 Jahre
|
3 Jahre
|
Objective Response Rate
Zeitfenster: an expected average of 6 weeks
|
an expected average of 6 weeks
|
Disease-free survival
Zeitfenster: an expected average of 6 weeks
|
an expected average of 6 weeks
|
Progression-Free Survival
Zeitfenster: an expected average of 6 weeks
|
an expected average of 6 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lin Chen, The Chinese PLA General Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.
- Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, Watanabe T. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014 Feb;21(2):539-46. doi: 10.1245/s10434-013-3208-y. Epub 2013 Aug 22.
- Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585. Epub 2013 Aug 5.
- Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H, Mochiki E. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. Ann Surg Oncol. 2015 Oct;22(11):3618-24. doi: 10.1245/s10434-015-4422-6. Epub 2015 Feb 7.
- Kanda T, Yajima K, Kosugi S, Ishikawa T, Ajioka Y, Hatakeyama K. Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. Gastric Cancer. 2012 Jul;15(3):235-44. doi: 10.1007/s10120-011-0100-y. Epub 2011 Oct 28.
- Inoue K, Nakane Y, Kogire M, Fujitani K, Kimura Y, Imamura H, Tamura S, Okano S, Kwon AH, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol. 2012 Feb;38(2):143-9. doi: 10.1016/j.ejso.2011.11.009. Epub 2011 Dec 9.
- Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. doi: 10.1200/JCO.2011.36.2236. Epub 2011 Aug 15.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen
- Neubildungen nach Standort
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Magenneoplasmen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Oxaliplatin
- Apatinib
Andere Studien-ID-Nummern
- Ahead-BG301
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Magenkrebs
-
Assiut UniversityNoch keine RekrutierungGAVE - Gastric Antral Vascular Ectasie
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... und andere MitarbeiterSuspendiertBlutung | GAVE - Gastric Antral Vascular Ectasie | Blutender MagenVereinigte Staaten
Klinische Studien zur Apatinib
-
Lei LiAbgeschlossenChemotherapie | Rezidivierendes Zervixkarzinom | Apatinib | Gezielte Therapie | Persistierendes fortgeschrittenes Zervixkarzinom | Hemmer des vaskulären endothelialen Wachstumsfaktors 2China
-
Peking University Cancer Hospital & InstituteRekrutierung
-
The First Affiliated Hospital of Zhengzhou UniversityRekrutierungSpeiseröhrenkrebs nach AJCC V8-StadiumChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Rekrutierung
-
The First Affiliated Hospital of Zhengzhou UniversityRekrutierung
-
Peking Union Medical College HospitalAbgeschlossenCholangiokarzinom | Hepatobiliäres Neoplasma | Gallengangskrebs | BiomarkerChina
-
Peking Union Medical College HospitalAbgeschlossen
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.RekrutierungSchwangerschafts-Trophoblastische NeoplasieChina
-
Beijing HospitalChinese Society of Clinical OncologyRekrutierung
-
Ruijin HospitalAktiv, nicht rekrutierendAdenokarzinom des Magen- und gastroösophagealen Übergangs (GEJ).China